Know Cancer

or
forgot password

Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas


Phase 2
18 Years
N/A
Open (Enrolling)
Both
WT1 Expressing Carcinoma

Thank you

Trial Information

Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas


Inclusion Criteria:



- Metastatic cancer, no standard treatment option

- Resected cancer with minimal residual disease, no standard treatment option

- WT-1 expression

- HLA-A2

Exclusion Criteria:

- Concurrent chemotherapy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Clinical efficacy

Principal Investigator

Ulrich Keilholz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Charité CBF

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

HaemaCBFWT104

NCT ID:

NCT00153608

Start Date:

April 2004

Completion Date:

Related Keywords:

  • WT1 Expressing Carcinoma
  • Carcinoma

Name

Location